OKYO Pharma Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Cash & Equivalents	14.59	1.56	0.83	4.05	2.7
Short-Term Investments	6	-	-	-	-
Cash & Short-Term Investments	20.59	1.56	0.83	4.05	2.7
Cash Growth	1219.38%	88.78%	-79.56%	49.70%	-60.78%
Other Receivables	0.38	2.11	0.71	1.15	1.6
Total Trade Receivables	0.38	2.11	0.71	1.15	1.6
Total Current Assets	20.97	3.68	1.54	5.2	4.3
Net Property, Plant & Equipment	0.01	0	0	0.01	0.01
Total Assets	20.98	3.68	1.54	5.2	4.3
Accounts Payable	8.64	9.23	7.42	5.04	1.35
Short-Term Debt	-	-	-	2.22	-
Total Current Liabilities	8.64	9.23	7.42	7.26	1.35
Total Liabilities	8.64	9.23	7.42	7.26	1.35
Additional Paid-in Capital	176.44	148.95	147.96	135.1	103.98
Accumulated Other Comprehensive Income	-12.13	-11.47	-11.31	-11.45	-0
Retained Earnings	-151.97	-143.02	-142.52	-125.7	-101.03
Shareholders' Equity	12.34	-5.55	-5.88	-2.05	2.95
Total Liabilities & Equity	20.98	3.68	1.54	5.2	4.3
Total Debt	0	0	0	2.22	0
Net Cash (Debt)	20.59	1.56	0.83	1.83	2.7
Net Cash Growth	1219.38%	88.78%	-54.82%	-32.27%	-60.58%
Net Cash Per Share	35.07	2.57	1.83	5.34	11.66
Book Value	12.34	-5.55	-5.88	-2.05	2.95
Book Value Per Share	21.00	-9.13	-13.02	-6.00	12.72
Tangible Book Value	12.34	-5.55	-5.88	-2.05	2.95
Tangible Book Value Per Share	21.00	-9.13	-13.02	-6.00	12.72

SEC Filings: 10-K · 10-Q